Pharmacovigilance Market Value Projected to Expand by 2023-2032

Comments · 16 Views

The global pharmacovigilance market size is expected to be worth around USD 19 billion by 2032 from USD 7.8 billion in 2022, growing at a CAGR of 9.3% during the forecast period from 2022 to 2032.

Introduction to Pharmacovigilance Market :

Pharmacovigilance is vital for various reasons. Firstly, it helps in safeguarding patient health. By actively monitoring drugs and medical devices, potentially harmful issues can be identified early, reducing the harm caused to patients. Secondly, it ensures regulatory compliance, as pharmaceutical companies are obligated to report any adverse events related to their products.

The global pharmacovigilance market size is expected to be worth around USD 19 billion by 2032 from USD 7.8 billion in 2022, growing at a CAGR of 9.3% during the forecast period from 2022 to 2032.

For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2032 – Please check this report:https://market.us/report/pharmacovigilance-market/

Fastest Growing Market:

  1. Market Expansion: The pharmacovigilance market is expanding rapidly due to the increasing complexity of drugs and medical devices, leading to higher demand for safety monitoring.
  2. Global Reach: The market’s growth is driven by its global reach, as pharmaceutical companies worldwide seek pharmacovigilance services to comply with stringent regulatory requirements.

Market Regional Analysis:

-North America [United States, Canada, Mexico]
-South America [Brazil, Argentina, Columbia, Chile, Peru]
-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
-Middle East Africa [GCC, North Africa, South Africa]
-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

Market Key Players:

  • Accenture plc
  • Bristol-Myers Squibb Company
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • GlaxoSmithKline plc
  • ICON plc
  • Novartis AG
  • Hoffmann-La Roche Ltd.
  • PAREXEL International Corporation
  • Pfizer Inc.
  • ICON plc
  • Wipro Limited

Market Top Segmentations:

Based By Service Provider

  • In-house
  • Contract Outsourcing
  • Others

Based On the Product Life Cycle

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Based By Type

  • Spontaneous Monitoring
  • Intensified ADR Monitoring
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • Others

Based By Process Flow

  • Case Data Management
  • Signal Detection
  • Risk Management System
  • Others

Based By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiology
  • Pulmonology
  • Others

Based By End-User

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Make an inquiry before picking up this report  @https://market.us/report/pharmacovigilance-market/#inquiry

Challenges and Opportunities:

Challenges:

  1. Data Overload: Handling and analyzing vast amounts of data related to adverse events can be overwhelming, posing a significant challenge to pharmacovigilance professionals.
  2. Signal Detection: Identifying genuine safety signals amidst the noise of data is a complex task, requiring advanced analytical tools and expertise.

Opportunities:

  1. Technological Advancements: The integration of artificial intelligence, machine learning, and big data analytics offers opportunities to streamline pharmacovigilance processes and improve efficiency.
  2. Global Expansion: The globalization of pharmacovigilance presents opportunities to tap into emerging markets and expand service offerings.

Contact:

Global Business Development Team – Market.us

Market.us (Powered by Prudour Pvt. Ltd.)

Send Email: [email protected]

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Tel: +1 718 618 4351

Website: https://market.us

Comments